Exhibit 99.1 scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of 16millioninthesecondquarterof2025;up9916 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remains on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of 16millioninthesecondquarterof2025;up9940.8 million as ...
scPharmaceuticals (US:SCPH)2025-08-08 04:01